MSD Completes Acquisition of Terns Pharmaceuticals to Expand CML Pipeline
Merck & Co. has completed its acquisition of Terns Pharmaceuticals, enhancing its pipeline for chronic myeloid leukaemia treatments. The deal makes Terns a wholly owned subsidiary and includes the FDA's breakthrough therapy designation for TERN-701.
Topics: CML pipeline expansion FDA breakthrough therapy Pharmaceuticals